I. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, Munich, Germany,
Clin Res Cardiol. 2014 May;103(5):353-62. doi: 10.1007/s00392-013-0659-x. Epub 2013 Dec 28.
This study aims to determine safety and efficacy of different stent types for extracranial vertebral artery stenting (EVAS) at a single-center institution.
Although endovascular revascularization techniques are well established for a variety of arterial vessel territories, its role within the vertebrobasilar system is less well defined.
We retrospectively analyzed all EVAS procedures performed at our institution between 1997 and 2012.
A total of 35 EVAS procedures were attempted in 35 patients with symptomatic occlusive extracranial vertebral artery (EVA) disease. Carotid self-expanding bare-metal stents (BMS-SE; n = 18), coronary balloon-expandable bare-metal stents (BMS-BE; n = 7) or drug-eluting stents (DES-BE; n = 16) were used according to physician's choice. The overall technical and clinical success rate was 100 and 94 %, respectively. Periprocedural complications included one death 14 days after intervention due to complications of initial stroke and 3 (9 %) patients with access site complications. Follow-up after a median of 18 ± 21 months yielded an overall in-stent restenosis rate of 23 % and a recurring clinical symptoms rate of 20 % whereas both endpoints were closely associated as 83 % of patients with recurring symptoms showed significant restenosis. Concerning the stent type, BMS-SE were associated with a significant higher in-stent restenosis rate compared to balloon-expandable stents (p = 0.012), and although not statistically significant, there was a clear trend towards a lower in-stent restenosis rate in drug-eluting compared to bare-metal stents (p = 0.068).
In patients with symptomatic extracranial vertebral artery disease, stenting is a safe and effective treatment option whereas balloon-expandable stents, and particularly drug-eluting stents, are superior to self-expanding stents.
本研究旨在确定单中心机构中颅外椎动脉支架置入术(EVAS)中不同支架类型的安全性和有效性。
尽管血管内血运重建技术已广泛应用于多种动脉血管区域,但在椎基底动脉系统中的作用尚未明确。
我们回顾性分析了 1997 年至 2012 年期间在我院进行的所有 EVAS 手术。
35 例有症状的颅外椎动脉(EVA)闭塞性疾病患者共尝试了 35 次 EVAS 手术。根据医生的选择,使用颈动脉自膨式裸金属支架(BMS-SE;n = 18)、冠状动脉球囊扩张裸金属支架(BMS-BE;n = 7)或药物洗脱支架(DES-BE;n = 16)。总的技术和临床成功率分别为 100%和 94%。围手术期并发症包括 1 例术后 14 天因初始中风并发症死亡和 3 例(9%)患者出现入路并发症。中位随访 18±21 个月后,支架内再狭窄率为 23%,复发临床症状率为 20%,且两个终点密切相关,83%有复发症状的患者显示明显再狭窄。关于支架类型,BMS-SE 与球囊扩张支架相比,支架内再狭窄率显著更高(p = 0.012),尽管差异无统计学意义,但药物洗脱支架与裸金属支架相比,支架内再狭窄率明显较低(p = 0.068)。
在有症状的颅外椎动脉疾病患者中,支架置入是一种安全有效的治疗选择,而球囊扩张支架,特别是药物洗脱支架,优于自膨式支架。